A Double-blind, Double-dummy, Randomized, 4-period Cross-over, Placebo- and Positive-controlled Study to Evaluate the Effect of TMC435 on the QTc Interval in Healthy Subjects.

Trial Profile

A Double-blind, Double-dummy, Randomized, 4-period Cross-over, Placebo- and Positive-controlled Study to Evaluate the Effect of TMC435 on the QTc Interval in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 May 2013

At a glance

  • Drugs Moxifloxacin; Simeprevir
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 07 Dec 2011 Actual initiation date changed from 1 Feb 2011 to 1 Jan 2011 as reported by ClinicalTrials.gov.
    • 07 Dec 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
    • 07 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top